Prof. Levanon Erez – Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade

Prof. Erez Levanon

Abstract Most patients with cancer either do not respond to immune checkpoint blockade or develop resistance to it, often because of acquired mutations that impair antigen presentation. Here we show that loss of function of the RNA-editing enzyme ADAR1 in tumour cells profoundly sensitizes tumours to immunotherapy and overcomes resistance to checkpoint blockade. In the…

Read More